Home › Freenome Raises $65M in Series A Funds

Freenome Raises $65M in Series A Funds

Mar 01, 2017

NEW YORK (GenomeWeb) – Palo Alto, California-based Freenome announced today that it has raised $65 million in Series A funding, which it will put toward conducting clinical trials to validate its non-invasive, early cancer detection technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

What's Popular?

In Molecular Diagnostics

  1. Liquid Biopsy Panel Expansion Enables Admera Health to Add Immunotherapy Prediction

    Premium

  2. Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk

    Premium

  3. Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

  4. Curetis Subsidiary Ares Ramping Up NGS Antibiotic Resistance Testing Business

    Premium

  5. BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsies

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.